Research Focus
Genetic variations affecting neurotransmitter systems in OCD (e.g. SLC6A4, DRD4) constitute the biological basis of the disease. CYP450 enzyme variants (CYP2D6, CYP2C9, CYP2C19, CYP1A2, CYP3A4) that affect the efficacy of SSRIs used in treatment are of great importance in terms of pharmacogenetics.
The OCD Working Group, which operates within the Center for Personalized Treatment (KİMER), continues its work with an innovative vision aiming to analyze the genetic and pharmacogenetic basis of OCD. This group focuses on the following goals with the aim of developing individualized treatment strategies:
Goals of the Study Group:
- Pharmacogenetic Perspective: To examine the role of genetic factors in the metabolism of drugs used in the treatment of OCD
- Genetic Predisposition: Identifying genetic variations that confer risk for OCD and creating models that can provide risk prediction.
- Clinical Applications: Developing genetic-based personalized treatment panels that can be used in the treatment of OCD.
These focal points have both scientific and clinical potential for the individualized treatment of OCD. By integrating genetic data into clinical practice, the working group aims to develop strategies that optimize each individual's response to treatment.